Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07319845 | A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes | PHASE2 | NOT YET_RECRUITING | 27 | — | — | Feb 6, 2026 | Jan 10, 2033 | Jan 6, 2026 | - | — |
Transfusion independence is defined as the absence of any red blood cells (RBC) transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.
| Arm | Type | Description |
|---|---|---|
| TAK-226 | EXPERIMENTAL | Participants will receive the study drug, TAK-226, administered subcutaneously every four weeks (Q4W), up to 48 weeks or until the end of for approximately one year during Treatment Period. |
| Name | Type | Description |
|---|---|---|
| TAK-226 | DRUG | TAK-226 subcutaneous injection |
Inclusion Criteria: 1. Participants or their legally authorized representative must be willing and able to sign the ICF and to adhere to the protocol requirements. 2. Japanese adult male or female participant ≥18 years of age at the time of signing informed consent. 3. Diagnosis of MDS with or with...